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A B S T R A C T
Background
Acute toxoplasma retinochoroiditis causes transient symptoms of ocular discomfort and may lead to permanent visual loss. Antibiotic
treatment aims primarily to reduce the risk of permanent visual loss, recurrent retinochoroiditis, and the severity and duration of acute
symptoms. There is uncertainty about the effectiveness of antibiotic treatment.
Objectives
To compare the effects of antibiotic treatment versus placebo or no treatment for toxoplasma retinochoroiditis.
Search methods
We searched CENTRAL (which contains the Cochrane Eyes and Vision group Trials Register) (2016, Issue 1), OvidMEDLINE, Ovid
MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to February
2016), EMBASE (January 1980 to February 2016), Latin American andCaribbean Health Sciences Literature Database (LILACS) (Jan-
uary 1982 to February 2016), the ISRCTN registry (www.isrctn.com/editAdvancedSearch), ClinicalTrials.gov (www.clinicaltrials.gov),
and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en).
We did not use any date or language restrictions in the electronic searches for trials. We last searched the electronic databases on 22
February 2016. We searched the reference lists of identified articles and contacted pharmaceutical companies for unpublished trials.
Selection criteria
We included randomised controlled trials that compared any antibiotic treatment against placebo or no treatment. We excluded trials
that included immunocompromised participants. We considered any antibiotic treatment known to be active against Toxoplasma gondii.
Antibiotic treatment could be given in any dose orally, by intramuscular injection, by intravenous infusion, or by intravitreal injection.
Data collection and analysis
The primary outcomes for this review were visual acuity at least three months after treatment and risk of recurrent retinochoroiditis.
Secondary outcomes were improvement in symptoms and signs of intraocular inflammation, size of lesion, and adverse events. We used
standard methodological procedures expected by Cochrane.
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Main results
Four trials that randomised a total of 268 participants met the inclusion criteria. In all four studies antibiotic was administered orally.
One study conducted in Brazil in both adults and children compared trimethoprim-sulfamexacocol over 20 months to no treatment
and was judged to be at high risk of performance, detection, and attrition bias. The other three studies compared antibiotic treatment
to placebo. We judged these three studies to be at a mixture of low or unclear risk of bias due to poor reporting. One study conducted
in the US in adults studied pyrimethamine-trisulfapyrimidine for eight weeks; one study conducted in the UK in children and adults
evaluated pyrimethamine for four weeks; and one study conducted in Brazil in adults investigated trimethoprim-sulfamethoxazole
for 12 months. In the last study, all participants had active retinochoroiditis and were treated with antibiotics for 45 days prior to
randomisation to trimethoprim-sulfamethoxazole versus placebo.
Only the study in Brazil of trimethoprim-sulfamethoxazole over 12 months, in participants with healed lesions, reported the effect of
treatment on visual acuity. People treated with antibiotics may have a similar change in visual acuity compared with people treated
with placebo at one year (mean difference -1.00 letters, 95% confidence interval (CI) -7.93 to 5.93 letters; 93 participants; low-quality
evidence).
Treatment with antibiotics probably reduces the risk of recurrent retinochoroiditis compared with placebo (risk ratio (RR) 0.26, 95%
CI 0.11 to 0.63; 227 participants; 3 studies; I2 = 0%; moderate-quality evidence); similar results were seen for acute and chronic
retinochoroiditis.
The UK study of pyrimethamine for four weeks reported an improvement in intraocular inflammation in treated compared with
control participants (RR 1.76, 95% CI 0.98 to 3.19; 29 participants; low-quality evidence). The study in Brazil of trimethoprim-
sulfamethoxazole for 12 months stated that the severity of inflammation was higher in the comparator group when compared to the
antibiotic-treated group but did not provide further details. In the US study of pyrimethamine-trisulfapyrimidine for eight weeks
intraocular inflammation had almost completely resolved by eight weeks in all participants, however in this study all participants
received steroid treatment.
Two studies (UK and US studies) reported an increased risk of adverse events in treated participants. These were a fall in haemoglobin,
leucocyte, and platelet count, nausea, loss of appetite, rash, and arthralgia.
Authors’ conclusions
Treatment with antibiotics probably reduces the risk of recurrent toxoplasma retinochoroiditis, but there is currently no good evidence
that this leads to better visual outcomes. However, absence of evidence of effect is not the same as evidence of no effect. Further trials
of people with acute and chronic toxoplasma retinochoroiditis affecting any part of the retina are required to determine the effects of
antibiotic treatment on visual outcomes.
P L A I N L A N G U A G E S U M M A R Y
Antibiotics compared with no treatment or placebo for the treatment of toxoplasma retinochoroiditis
Review question
Are antibiotics an effective treatment for toxoplasma retinochoroiditis?
Background
Toxoplasma retinochoroiditis occurs when a parasite calledToxoplasma gondii gets into the retina (the light-sensitive layer inside the eye)
and the choroid (layer of the eyeball near the retina). This causes inflammation that can scar the retina and reduce vision. Symptoms
include a sudden feeling of discomfort in the eye and loss of vision, which usually resolve spontaneously within six to eight weeks. The
infection can keep returning, increasing the chances of damage. Antibiotics are sometimes used to try to reduce the inflammation and
scarring, or to prevent the infection from re-emerging, but it is unclear how well they work.
Study characteristics
We found four studies with a total of 268 participants. These studies were conducted in Brazil, the UK, and the US. The evidence is
current to 22 February 2016.
Key results
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Only one of the four studies compared the effect of antibiotic treatment for 12 months with placebo on visual acuity and found
similar changes in both groups. Three studies examined the effect of antibiotics on reducing the number of recurring episodes of the
disease. Two of these three studies were conducted in Brazil in adults infected with the more aggressive South American strains of the
parasite, which can cause frequently recurring eye symptoms. The studies from Brazil found that the long-term antibiotics over 14 and
12 months, respectively, reduced the number of recurrent episodes of retinochoroiditis. The other study did not find that short-term
(eight weeks) treatment with antibiotics made any difference. Two studies reported an improvement in intraocular inflammation in
antibiotic-treated compared with untreated participants, and one study reported no changes. Two studies investigated side effects of
giving antibiotics such as decreased white blood cells, loss of appetite, rashes and other allergic reactions and found only weak evidence
that antibiotics increase the risk of side effects.
Quality of the evidence
There were problems with the design, conduct, and analyses of all of the studies, which could have biased the results. There was a
lack of evidence about whether antibiotics (short or long term) prevent vision loss. More trials are needed, including trials of newer
antibiotics.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Antibiotic versus no treatment for toxoplasma retinochoroiditis
Patient or population: People with toxoplasma ret inochoroidit is
Settings: Primary care
Intervention: Antibiot ic1
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Antibiotic
Change in visual acuity
Follow-up: 12 months
Measured as number of
let ters read on an ET-
DRS chart; higher num-
ber of let ters = better
vision
People in the control
group gained on aver-
age 22 letters over 12
months
People in the ant ibiot ic
group gained on aver-
age 1 fewer letters (95%
CI 8 less to 6 more)
- 93
(1 study)
⊕⊕⊕©
low2,3
-
1 or more recurrences
of retinochoroiditis
Follow-up: 8 weeks to
24 months
Low risk (e.g. US/ UK) RR 0.26
(0.11 to 0.63)
227
(3 studies)
⊕⊕⊕©
moderate4
-
100 per 1000 26 per 1000 (11 to 63)
High risk (e.g. Brazil)
250 per 1000 65 per 1000
(28 to 158)
Improvement in in-
traocular inflammation
Follow-up: 4 weeks
Study population RR 1.76
(0.98 to 3.19)
29
(1 study)
⊕⊕©©
low2
Study conducted in the
UK (pyrimethamine for
4 weeks)500 per 1000 880 per 1000
(490 to 1000)
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Size of lesion
Follow-up: 4 weeks to
24 months
See comment None of the included
studies reported this
outcome
Adverse events
Follow-up: 8 weeks to
24 months
Study population RR 3
(0.37 to 24.17)
20
(1 study)
⊕⊕©©
low5
Study conducted in
the US (pyrimethamine-
trisulfapyrim idine for 8
weeks)
Adverse events in-
cluded nausea, loss of
appet ite, rash, arthral-
gia, and low platelet
count
100 per 1000 300 per 1000
(37 to 1000)
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; RR: Risk rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Dif ferent combinat ions were used. One RCT used pyrimethamine (200 mg/ day 1, 100 mg/ day 2, 50 mg/ day on days 3 to 15,
25 mg/ day on days 16 to 56); trisulfapyrim idine 2 g/ day for 8 weeks; prednisolone (40 mg/ day on days 1 to 7, 20 mg/
day on days 8 to 56). Other RCT used trimethoprim-sulfamethoxazole tablet (800 mg/ 160 mg) every 2 days for 12 months,
while remaining RCTs used pyrimethamine (Daraprim) 25 mg daily for 4 weeks versus inert tablet and trimethoprim 160 mg
and sulfamexacocol 800 mg, both orally every 3 days for 20 months, respect ively.
2Downgraded for imprecision (-1): the conf idence interval was compatible with both benef it and harm and included clinically
meaningful ef fects.
3Downgraded for indirectness (-1): trial was a dif ferent design to others and evaluated ant ibiot ic treatment af ter lesions had
been successfully treated.
4Downgraded for risk of bias (-1): in one RCT, medicat ion was administered in an unmasked fashion, part icipants were
followed by the clinician responsible for the trial.
5Downgraded for imprecision (-2): there is very lit t le information owing to 20 part icipants, and the conf idence interval was
very wide.
ETDRS: Early Treatment Diabet ic Retinopathy Study
RCT: randomised controlled trial5
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B A C K G R O U N D
Description of the condition
Toxoplasma gondii (T.gondii) is a ubiquitous human parasite. In-
fection of the retina results in acute intraocular inflammation
(retinochoroiditis) and the formation of a retinochoroidal scar.
Retinochoroiditis can recur at any time, often years after first in-
fection, and may be due to the local release of T.gondii parasites
from cysts in the retina (Holland 2003). Alternatively, retinal anti-
gens normally hidden from immune surveillance may be released
due to cyst reactivation and stimulate an inflammatory response
(Roberts 1999).
Acute toxoplasma retinochoroiditis may cause sudden onset of vi-
sual loss and pain, sometimes associated with floaters or photo-
phobia. Symptoms often resolve spontaneously within six to eight
weeks, leaving a healed retinochoroidal scar (Rothova 1993a).
Scars involving the posterior pole (within the macular arcade or
near the optic nerve head) or very large lesions leading to vitreous
opacifications can permanently impair visual acuity. Peripheral le-
sions may cause field defects but are unlikely to affect visual acuity.
The lifetime risk of symptoms due to acute toxoplasma
retinochoroiditis ranges from 18 out of 100,000 (95% confidence
interval (CI) 11 to 25) for people born in the UK to 382 out
of 100,000 (95% CI 99 to 664) for people born in West Africa
(Gilbert 1999). The presentation of retinochoroiditis following
prenatal or postnatal infection is similar and can only be distin-
guished in people with systemic signs of toxoplasmosis (Gilbert
1999). The risk of retinochoroiditis after prenatal toxoplasmosis
is 20% in the early childhood years (Dunn 1999; Guerina 1994;
Lebech 1999), and may be as high as 80% by adolescence (Koppe
1986). Less information is available on the risk of retinochoroidi-
tis after postnatal infection; reports range from 0.3% to 0.7% one
year after infection, in Burnett 1998, to 3% (duration of follow-up
unknown), in Perkins 1973. However, as prenatal toxoplasmosis is
approximately 1000 times less common than postnatally acquired
infection, the vast majority of toxoplasma retinochoroiditis seen
by ophthalmologists is due to postnatal infection (Gilbert 2000a).
Much higher rates of toxoplasma infection and ocular disease are
seen in South America than in North America and Europe, and
ocular manifestations are more severe in South America (Gilbert
2008).
Description of the intervention
The aim of treatment for toxoplasma retinochoroiditis is to re-
duce the risk of permanent visual impairment (by reducing the
size of the retinochoroidal scar), the risk of recurrence (Rothova
1993b), and the severity and duration of acute symptoms. Antibi-
otics are usually given for six to eight weeks. Adjunctive steroid
therapy may sometimes be used to reduce the duration and sever-
ity of acute symptoms due to intraocular inflammation. Infants
with prenatal toxoplasmosis but without retinochoroiditis are of-
ten given prophylactic treatment for a year or more to reduce the
risk of retinochoroiditis (Dunn 1999).
How the intervention might work
Antibiotic treatment is thought to eradicate the tachyzoite form of
the parasite during the acute inflammatory phase. Antibiotics are
not effective against the latent bradyzoite cyst form of the parasite.
Why it is important to do this review
There is uncertainty about the effectiveness of antibiotic treatment
for toxoplasma retinochoroiditis (Holland 2004). As a result, the
type of antibiotics prescribed varies (Engstrom 1991), and some
clinicians do not treat patients with acute retinochoroiditis in the
periphery of the retina (Rothova 1993b). In addition, the antibi-
otics used have adverse effects. We systematically reviewed the ev-
idence for the effectiveness of antibiotic treatment for toxoplasma
retinochoroiditis.
The protocol for this review was published on the Cochrane Li-
brary (Gilbert 2000b).
O B J E C T I V E S
To compare the effects of antibiotic treatment compared with
placebo or no treatment for toxoplasma retinochoroiditis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included published and unpublished randomised controlled
trials (RCTs).
Types of participants
We included studies involving participants of any age with
retinochoroiditis likely to be due to toxoplasmosis. We included
people treated for acute retinochoroiditis or those with healed scars
who were treated prophylactically to prevent new lesions. We ex-
cluded any studies involving a majority of immunocompromised
participants, as the presentation and clinical course of the disease
differs to that in immunocompetent people.
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Types of interventions
We included any antibiotic treatment known to be active against
Toxoplasma gondii that was compared against placebo or no treat-
ment. Antibiotic treatment could be given in any dose orally, by
intramuscular injection, by intravenous infusion, or by intravitreal
injection.
Types of outcome measures
Primary outcomes
We considered that treatment is given to prevent long-term visual
impairment, which can only be assessed after the acute inflamma-
tion has subsided. Our primary outcomes were therefore:
• visual acuity or change in visual acuity (using any measure)
at least three months after the start of treatment;
• risk of one or more recurrences of retinochoroiditis at the
end of follow-up (of any duration).
Secondary outcomes
A secondary aim of treatment is to reduce the severity and duration
of pain and visual loss due to acute inflammation. Our secondary
outcomes were:
• duration and severity of symptoms of visual impairment
and ocular discomfort due to acute retinochoroiditis (any
measure);
• size of lesion at the end of follow-up (any measure), as this
affects the degree of long-term visual impairment;
• adverse events (any mentioned). Possible adverse events
included decreased platelet or white blood cell count,
gastrointestinal symptoms, rashes and other allergic phenomena.
Search methods for identification of studies
Electronic searches
We searched CENTRAL (which contains the Cochrane Eyes
and Vision group Trials Register) (2016, Issue 1), Ovid MED-
LINE, Ovid MEDLINE In-Process and Other Non-Indexed Ci-
tations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January
1946 to February 2016), EMBASE (January 1980 to February
2016), Latin American and Caribbean Health Sciences Literature
Database (LILACS) (January 1982 to February 2016), the IS-
RCTN registry (www.isrctn.com/editAdvancedSearch), Clinical-
Trials.gov (www.clinicaltrials.gov), and the World Health Orga-
nization (WHO) International Clinical Trials Registry Platform
(ICTRP) (www.who.int/ictrp/search/en).We did not use any date
or language restrictions in the electronic searches for trials. We
last searched the electronic databases on 22 February 2016. We
searched the reference lists of identified articles and contacted
pharmaceutical companies for unpublished trials.
See: Appendices for details of search strategies for CENTRAL
(Appendix 1),MEDLINE (Appendix 2), EMBASE (Appendix 3),
LILACS (Appendix 4), ISRCTN (Appendix 5), ClinicalTrials.gov
(Appendix 6), and the ICTRP (Appendix 7).
Searching other resources
We also contacted the pharmaceutical companies that produce
drugs licensed for the treatment of toxoplasmosis for any unpub-
lished trials, and we scrutinised reference lists from review articles
and published trials. We searched the abstracts from the confer-
ence proceedings of ARVO (Association for Research in Vision
and Ophthalmology) (available from 1980 to 2001, with key-
words from 1988) and reports of international symposia on uveitis
using keywords ’antibiotic’, ’choroiditis’, ’retinochoroiditis’, ’tox-
oplasma’, ’toxoplasmic’ and ’toxoplasmosis’.
Data collection and analysis
Selection of studies
Two review authors (Sarah See and Leanne Jones) independently
reviewed titles and abstracts of all studies and retrieved potentially
relevant studies in hard copy. Another two review authors (RG
and MS) reviewed the hard copies against the inclusion criteria.
Disagreements were resolved by consensus. We contacted the au-
thors of trials that appeared to meet the inclusion criteria but did
not report sufficient data.
For the update in 2016, EP and SB screened search results.
Data extraction and management
Two review authors (MS and RG) independently extracted rele-
vant details about the design (randomised or quasi-randomised,
concealment of allocation, and masking of outcome assessment)
and the results of each study.
For the update in 2016, EP and SB independently extracted data.
Assessment of risk of bias in included studies
Weassessed risk of bias in five domains: selectionbias, performance
bias, detection bias, attrition bias, and selective reporting bias. We
also commented on any other sources of bias. We classified the
risk of bias according to Chapter 8 of the Cochrane Handbook for
Systematic Reviews of Interventions as low risk, high risk, or unclear
(Higgins 2011).
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Measures of treatment effect
We planned to compare the risk of long-term visual impairment
based on the most clinically relevant measure reported. For the
other outcomes we summarised results in terms of the risk ratio
of:
1. one or more recurrences in the treatment compared with
no-treatment group;
2. improvement compared with the same or worsening acute
symptoms of visual impairment and ocular discomfort; and
3. adverse events.
Unit of analysis issues
All four included studies measured outcomes at the participant
level, that is a single observation per person.
Dealing with missing data
We planned to conduct an intention-to-treat analysis using im-
puted data if computed by the trial investigators using an appro-
priate method. However, the included studies did not report in-
tention-to-treat data, and so we have done an available-case anal-
ysis, which assumes that data are missing at random. We assessed
whether this assumption was reasonable by collecting data from
each included trial on the number of participants excluded or lost
to follow-up and reasons for loss to follow-up by treatment group.
Assessment of reporting biases
We used the ’Risk of bias’ assessment tool to look for selective or
incomplete reporting. See Assessment of risk of bias in included
studies.
If in future updates of this review 10 or more trials are included
in a meta-analysis, we will construct funnel plots and consider
tests for asymmetry for assessment of publication bias, according
to Chapter 8 of the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011).
Data synthesis
We used a random-effects model to calculate summary measures,
as eligible studies represented clinically varied populations of par-
ticipants.
Subgroup analysis and investigation of heterogeneity
When data were available, we considered acute and recurrent
retinochoroiditis separately.
Sensitivity analysis
We did not have enough data to do sensitivity analyses. In future
updates of this review we will do a sensitivity analysis excluding
studies at high risk of bias in one or more domains.
Summary of findings table
We prepared a ’Summary of findings’ table presenting relative and
absolute risks. We graded independently the overall quality of
the evidence for each outcome using the GRADE classification
(GRADEpro 2015). We included the following outcomes in the
’Summary of findings’ table. This list of outcomes was not pre-
specified because the ’Summary of findings’ table has only been
prepared in this (2016) update.
1. Visual acuity
2. Recurrence of retinochoroiditis
3. Intraocular inflammation
4. Size of lesion
5. Adverse effects
R E S U L T S
Description of studies
Results of the search
In the initial electronic search in 2000,we screened152 studies and
identified 10 that were potentially relevant. Three of these stud-
ies were not randomised controlled trials (Crespo 1993; Rothova
1993b; Theodossiadis 1989), a further three trials involved com-
parisons of different antibiotic regimens (Abreu 1988; Colin 1989;
Jeddi 1997), and one trial compared steroids versus no steroids
(Chodos 1961). Three studies met the inclusion criteria (Acers
1964; Perkins 1956; Silveira 2002).
Update searches
We updated the searches in December 2005 and screened 512
reports of trials, but did not find any new studies. We performed
further updates in January 2008 and February 2011, identifying
211 and 289 study reports, respectively. The Cochrane Informa-
tion Specialist (CIS) scanned the search results and removed any
references that were not relevant to the scope of the review. Both
search updates did not identify any references that met the inclu-
sion criteria for the review.
Update searches run in February 2016 identified 834 new records
(Figure 1). The CIS removed 128 duplicate records, screened the
remaining 706 records, and removed 661 records that were not
relevant to the scope of the review. We screened the remaining 45
records and discarded 44 reports as not relevant. We obtained one
full-text report (Felix 2014), which met the inclusion criteria for
the review; see Characteristics of included studies for details.
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Figure 1. Study flow diagram.
Included studies
See the Characteristics of included studies table.
The type of participant and type and duration of treatment varied.
Acers 1964 compared the effect of eight weeks of pyrimethamine-
trisulfapyrimidine versus lactose capsules in participants with
acute toxoplasma retinochoroiditis. In contrast, Silveira 2002
determined the effect of long-term (20 months) of prophylac-
tic trimethoprim-sulfamexacocol treatment compared with no
treatment in participants with chronic relapsing toxoplasma
retinochoroiditis. Felix 2014 evaluated the effect of 12 months
of prophylactic treatment with trimethoprim-sulphamethoxazole
compared with placebo in participants with healed lesions of ac-
tive recurrent toxoplasma retinochoroiditis. Perkins 1956 studied
the effects of four weeks of pyrimethamine (Daraprim) compared
with inert tablets in participants with acute uveitis due to any
cause. He presented results for the subgroup with posterior uveitis
that were toxoplasma antibody positive.
Felix 2014 reported on assessment of change in best corrected
visual acuity over the 12-month period as one of the primary
outcomes. None of the other three studies reported the effect of
treatment on vision. Three studies reported data on the primary
outcome of recurrent retinochoroiditis, at 12months (Felix 2014),
at 14 and 17 months (Silveira 2002), and at two years (Acers
1964). Three studies, Acers 1964, Perkins 1956, and Silveira 2002,
reported on changes in intraocular inflammation as assessed by the
ophthalmologist. This outcome was regarded as a measure of the
duration and severity of symptoms of acute inflammation, defined
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as a secondary outcome for this review. Two studies reported on
adverse events (Acers 1964; Perkins 1956).
Excluded studies
See the Characteristics of excluded studies table for study details.
Risk of bias in included studies
See Figure 2 and Figure 3.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
None of the four included studies made statements about alloca-
tion concealment. We assessed concealment of treatment alloca-
tion to be low risk of bias in the study by Felix 2014, as a nurse
enrolled and assigned participants in the interventions in amasked
fashion, and in Silveira 2002 ’closed’ envelopes were opened after
eligibility criteria had been confirmed (unpublished data). Perkins
1956 allocated participants to tablets labelled A or B but did not
mention how this allocation was concealed. Acers 1964 used a
random listing but did not describe allocation concealment.
Blinding
We assessed performance and detection bias as low risk in the three
studies that used inert tablets (Acers 1964; Felix 2014; Perkins
1956), although the similarity of these to the active treatment
was not specified. Consequently, clinicians may have been able to
deduce treatment allocation through scrutiny of the participant’s
treatment or by monitoring the results of blood counts (leuko-
cyte and platelet depression is common with pyrimethamine treat-
ment). Felix 2014 stated that participants were randomly assigned
to group 1 or group 2 and received interventions in a masked fash-
ion, while medical events were recorded monthly on a standard-
ised form by a member of the medical staff in a masked fashion.
Acers 1964 commented that the ophthalmologists who assessed
intraocular inflammation at eight weeks weremasked to treatment
but not for the assessment of recurrence during the two years of
the study. Perkins 1956 mentioned that the ophthalmic assessor
was unaware of treatment allocation and usually unaware of the
result for toxoplasma antibodies, but differences in the propor-
tions of participants receiving pyrimethamine (Daraprim) in the
dye test positive and negative groups raise the possibility of a lack
of masked outcome measures and breaches in allocation conceal-
ment. We judged the study by Silveira 2002 to be at high risk of
bias as participants were randomised to treatment or no treatment,
and the clinician who entered them into the study carried out the
follow-up assessments.
Incomplete outcome data
We rated attrition bias in the study by Felix 2014 as low as out-
comes were assessed over a 12-month period during which there
was a lost to follow-up of one in each group. Completeness of
follow-up was unclear for two studies (Acers 1964; Perkins 1956).
Acers 1964 assessed all participants at eight weeks’ post-treatment,
but the length of follow-up and number assessed for recurrence
during the two years of the study were not stated. Perkins 1956
reported results for a subgroup of 29 participants with posterior
uveitis and positive toxoplasma antibodies but did not state the
numbers of participants randomised to each group. A further con-
cern is that an unknown number of participants were excluded,
but it is not stated at what point in the study these exclusions
occurred. The study by Silveira 2002 provided unpublished data
showing that 10% of participants were lost to follow-up in both
arms at 14 months, but this rose to 31% for treated and 21% for
untreated participants by 17 months. We have therefore reported
results for 14 months.
Selective reporting
We rated the risk in Felix 2014 as unclear as the study protocol
was not available. We rated the other three studies as low risk for
selective reporting bias (Acers 1964; Perkins 1956; Silveira 2002).
Other potential sources of bias
One further concern about the study by Perkins 1956 is that it
is not clear whether the subgroup analyses according to site of
uveitis and presence of toxoplasma antibodies were predefined.
In addition, the four-week follow-up period was insufficient to
detect recurrence, hence there was high risk of bias toward no
effect (Perkins 1956).
Effects of interventions
See: Summary of findings for the main comparison Antibiotic
versus no treatment for toxoplasma retinochoroiditis
Primary outcomes
Visual acuity or change in visual acuity at least three months
after the start of treatment
In Felix 2014, there were similar changes in best corrected visual
acuity in the treatment and the placebo group at 12 months’ fol-
low-up (mean difference -1.00 letters, 95% confidence interval
(CI) -7.93 to 5.93; 93 participants) (Analysis 1.1).
None of the other studies provided results for long-term visual
outcomes.
One or more recurrences of retinochoroiditis at the end of
follow-up (of any duration)
The effect of treatment on recurrent retinochoroiditis was strongly
influenced by Silveira 2002, who reported results for participants
with relapsing retinochoroiditis treated for 14 months (risk ratio
(RR) of recurrence 0.29, 95%CI 0.10 to 0.81). Silveira 2002 took
place in Brazil, where the strain of Toxoplasma gondii is known
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to cause more frequent and more severe lesions than that seen
in Europe or North America. In another study from Brazil, Felix
2014 also reported a lower risk of recurrences of retinochoroiditis
with antibiotic treatment. In this study, treatment for 12 months
showed RR of 0.08, 95% CI 0.00 to 1.3. Acers 1964 reported
recurrent lesions in 1 out of 10 treated and 1 out of 10 untreated
participants after two years’ follow-up (RR 1.00, 95% CI 0.07 to
13.87).
The results of pooling these three studies was a pooled RR of
0.26, 95% CI 0.11 to 0.63; 227 participants; 3 studies; I2 = 0%
(Analysis 1.2). We considered acute and chronic retinochoroiditis
separately, but there was little evidence for any difference in effect,
however with only three studies the power of this analysis was low.
Secondary outcomes
Duration and severity of symptoms of visual impairment and
ocular discomfort due to acute retinochoroiditis (any
measure)
Two studies reported an improvement in intraocular inflammation
in treated compared with untreated participants (Perkins 1956;
Silveira 2002), and one study reported no difference (Acers 1964).
Perkins 1956 reported improvement in 76% of treated and 50%
of untreated participants (RR 1.76, 95%CI 0.98 to 3.19; Analysis
1.3). Silveira 2002 stated that the severity of inflammation was
higher in the control group but did not provide further details.
Acers 1964 stated that intraocular inflammation had almost com-
pletely resolved by eight weeks in all participants, and there was no
difference in the time to quiescence of lesions between treatment
groups. This was the only study where all participants received
steroid treatment.
Size of lesion at the end of follow-up (any measure)
This outcome was not reported.
Adverse events
Perkins 1956 reported adverse events for a group of uveitis partic-
ipants in addition to those with toxoplasma retinochoroiditis. It
was not clear whether this group included only randomised par-
ticipants, and so we did not pool results. Of those participants
treated with pyrimethamine (Daraprim), 53 out of 113 had a fall
in haemoglobin of more than 5%, and 3 out of 113 had a fall
in leukocyte count, compared with none of the 70 untreated par-
ticipants. Acers 1964 reported adverse events (nausea, loss of ap-
petite, rash, arthralgia, and stopping treatment due to low platelet
count) in 3 out of 10 treated compared with 1 out of 10 untreated
participants (RR 3.00, 95% CI 0.37 to 24.17).
D I S C U S S I O N
Summary of main results
See Summary of findings for the main comparison.
Four trials that randomised a total of 268 participants met the
inclusion criteria. Two studies were conducted in Brazil, one in
the UK, and one in the US. One study compared antibiotic to
no treatment and was judged to be at high risk of performance,
detection, and attrition bias. The other studies compared antibi-
otic treatment to placebo and were generally judged to be at a
mixture of low or unclear risk of bias due to poor reporting. Only
one study reported the effect of treatment on visual acuity and
found a similar change in visual acuity between antibiotic- and
placebo-treated groups at one year. Three studies reported results
for recurrent retinochoroiditis. There was a lower risk of recurrent
retinochoroiditis with antibiotic treatment; similar results were
seen for acute and chronic retinochoroiditis. Two studies reported
an improvement in intraocular inflammation in treated compared
with untreated participants, and one study reported no difference;
it was not possible to pool these data. Two studies found an in-
creased risk of adverse events in treated participants.
Overall completeness and applicability of
evidence
Overall, with only four relatively small studies, we cannot consider
the evidence adequate to inform policy; two of these studies were
conducted nearly 40 years ago, and one study was available in
abstract form only.
Two of the studies are from Brazil where the strain of Toxoplasma
gondii is known to cause more frequent and more severe lesions,
and so the results of this study may not apply to other parts of the
world.
None of the studies considered newer antibiotics such as clin-
damycin or azithromycin (which have a lower risk of adverse
events) with no treatment.
Quality of the evidence
We graded the quality of the evidence as moderate to low, down-
grading for imprecision and risk of bias, depending on the out-
come.
Agreements and disagreements with other
studies or reviews
Other reviews have also found a lack of evidence to support rou-
tine antibiotic treatment for toxoplasma retinochoroiditis, but
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evidence that treatment reduces recurrence (Harrell 2014; Kim
2013).
We found weak evidence to suggest that treatment involving
pyrimethamine increases the risk of adverse events. However, ad-
verse effects of pyrimethamine are well established (BNF 2001).
Our review did not include any trials of intravitreal antibiotics
because we did not find any RCTs comparing these with a control.
We identified two studies that compared intravitreal antibiotics
with oral antibiotics and therefore did not fall under the scope of
this review (Baharivand 2013; Soheilian 2011).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
We found a lack of evidence to support routine antibiotic treat-
ment for toxoplasma retinochoroiditis to prevent visual impair-
ment. We found weak evidence that the risk of recurrence of
retinochoroiditis is reduced after long-term treatment with sys-
temic antibiotics.
Implications for research
Randomised placebo-controlled trials are required to determine
the effectiveness of antibiotic treatment for people with acute
or chronic toxoplasma retinochoroiditis affecting any part of the
retina. Studies should ensure masked assessment of long-term
visual impairment, recurrent retinochoroiditis and duration of
symptoms and signs of acute inflammation. Low risk of adverse
events should be an important factor in the choice of antibiotic
for evaluation.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Acers 1964
Methods Participants allocated by a “random listing”
It was not clear whether 1 or both eyes were included
Participants Participants (n = 20) residing in Baltimore, USAwith active retinitis, positive toxoplasma
skin test and antibody test (dye test), and no other cause of retinitis. Mean age 32.9 years
(treatment), 30.9 years (controls) (age range 18 to 49 years)
Interventions Pyrimethamine (200 mg/day 1, 100 mg/day 2, 50 mg/day on days 3 to 15, 25 mg/day
on days 16 to 56); trisulfapyrimidine 2 g/day for 8 weeks; prednisolone (40 mg/day on
days 1 to 7, 20 mg/day on days 8 to 56) versus lactose capsules and prednisolone as above
Outcomes 1. Change between baseline and end of treatment at 8 weeks in:
i) visual acuity
ii) intraocular inflammation (classified as “improved versus same or worse”
based on visual acuity, media and lesion appearances)
iii) adverse events (nausea, loss of appetite, rash, arthralgia, stopped treatment
due to low platelet count)
2. Time to quiescence of lesion
3. Recurrence of lesions during the 2 years of the study (length and completeness of
follow-up unclear)
Outcomes assessed masked to treatment allocation at 8 weeks but not thereafter. Follow-
up complete at 8 weeks but not stated for the 2 years of the study
Notes Date study conducted: Not reported
Funding source: Training Grant No. 2B-5217, from the National Institute of Neurolog-
ical Diseases and Blindness, US Public Health Service
Declaration of interest: not reported
Trial registration: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random listing
Allocation concealment (selection bias) Unclear risk No relevant statement
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk A lactose capsule was used as a placebo:
“placed in identical bottles.”
Masking of ocular outcomes from clinical
data on side effects
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Acers 1964 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Separate, independent assessors were used
for clinical signs and for ophthalmic exam-
ination. The ophthalmic assessor “did not
inquire about, or obtain, any subjective in-
formation or laboratory data.”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Complete follow-up for 8 weeks, but this
would not be adequate for detecting recur-
rence
Completeness of follow-up over the entire
2-year study period unclear
Selective reporting (reporting bias) Low risk Recurrence was a secondary outcome, al-
though no details are given about the com-
pleteness of follow-up for this outcome
Felix 2014
Methods Participants randomly assigned. Randomisation 1:1, stratified by sex and block sizes of
4
It was not clear whether 1 or both eyes were included
Participants Participants (n = 95) > 18 years of age, from public hospital in Campinas, Brazil who had
healed lesions on completion of treatment with a tablet of trimethoprim-sulfamethoxa-
zole (800 mg/160 mg) 2 times daily for 45 days for active recurrent Toxoplasma gondii
retinochoroiditis (defined as a new focus of necrotising retinochoroiditis with active in-
flammation either adjacent to or remote from pre-existing retinochoroidal scars, with
positive immunoglobulin G for toxoplasmosis). Mean age, male/female ratio, and base-
line BCVA: 34 years, 20/27, 20/80 (treatment); 33 years, 22/26, 20/100 (controls)
Interventions 1 trimethoprim-sulfamethoxazole tablet (800 mg/160 mg) every 2 days (treatment) and
1 identical placebo tablet containing starch every 2 days (control)
Outcomes 1. Recurrent toxoplasmosis retinochoroiditis within 12 months
2. Change in BCVA over 12 months
Outcomes assessed for 12-month period only. Recurrences beyond 12 months not as-
sessed
Notes Date study conducted: 24 August 2011 to 28 August 2012
Funding source: Fundac¸a~o de Amparo a Pesquisa do Estado de Sa~o Paulo, protocol
2010/15980-2
Declaration of interest: not reported
Trial registration: Influence of trimethoprim-sulfamethoxazole for the recurrence of oc-
ular toxoplasmosis; clinicaltrials.gov identifier: NCT01449877; http://clinicaltrials.gov/
show/NCT01449877
Risk of bias
18Antibiotics versus no treatment for toxoplasma retinochoroiditis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Felix 2014 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was 1:1 and was stratified
by sex, and block sizes of 4 were used
Allocation concealment (selection bias) Unclear risk Nurse enrolled and assigned participants in
the interventions in a masked fashion
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants were randomly assigned to
group 1 or group 2 and received interven-
tions in a masked fashion
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Medical events were recorded monthly on
a standardised form by a member of the
medical staff in a masked fashion
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1 lost to follow-up in each group
Selective reporting (reporting bias) Unclear risk Study protocol not available. Primary
outcome, incidence of recurrences of
retinochoroiditis, and secondary outcome,
changes in BCVA, were well explained in
report
Perkins 1956
Methods Allocation of tablets labelled A or B according to random list
It was not clear whether 1 or both eyes were included
Participants Uveitis participants (n = 164) enrolled at first attendance at uveitis clinic, London, UK.
Subgroup analyses presented for participants with a positive toxoplasma antibody dye
test and posterior uveitis (n = 29). Varying age group from (1 to 19) years to 60+
Interventions Pyrimethamine (Daraprim) 25 mg daily for 4 weeks versus inert tablet
Outcomes No improvement versus improvement in signs of intraocular inflammation at 4 weeks (in
29 people with posterior uveitis and toxoplasma antibodies). Adverse events: depressed
leucocyte count (for all uveitis participants only; n = 113 treated and 70 untreated)
Ophthalmic assessor unaware of treatment allocation and usually unaware of dye test
result. Proportion receiving pyrimethamine (Daraprim) in dye test positive versus neg-
ative groups differs, raising the possibility of breaches of allocation concealment
Notes Date study conducted: Not reported.
Funding source: Not reported.
Declaration of interest: Not reported.
Trial registration: Not reported.
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Perkins 1956 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “...distributed according to a random list.”
Allocation concealment (selection bias) Unclear risk No statement relevant to allocation con-
cealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “The clinician in charge of the patient does
not know which of the two tablets the pa-
tient has received.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The person making the assessment did
not know whether the patient had received
Daraprim or the inert tablets.”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “Some patients had to be excluded because
of difficulty in follow-up or interruption
of treatment by intercurrent illness.” These
participants do not appear to have been
counted in the results
Selective reporting (reporting bias) Low risk The only outcome reportwas improvement
in symptoms
Silveira 2002
Methods Randomised using sealed envelopes (information from authors)
Participant could have retinochoroidal lesion in 1 or both eyes
Participants Participants with chronic recurrent toxoplasma retinochoroiditis, south Brazil (treated n
= 61 (28 unilateral and 33 bilateral disease) (age range 8 to 50 years); untreated n = 63
(35 unilateral and 28 bilateral disease) (age range 7 to 53 years))
Interventions Trimethoprim 160 mg and sulfamexacocol 800 mg, both orally every 3 days for 20
months versus no treatment
Outcomes 1. Recurrence of 1 or more retinochoroidal lesions by 14 months
2. Mean time to first recurrence
3. Intraocular inflammation at unspecified time point based on visual acuity and
anterior chamber inflammation
Published paper does not report losses to follow-up; we obtained this information from
authors. At 14 months, 6 lost in treatment group, 4 lost in control group. At 17 months,
19 lost in treatment group and 13 in control group. No data given on visual acuity
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Silveira 2002 (Continued)
Notes Date study conducted: April 1998 to not reported
Funding source: ConselhoNacional deDesenvolvimentoCient ´ f ´ co e Tecnolo´ gico
(CNPq), Coordenac¸a~o de Aperfeic o¸amento de Pessoal de N ´ vel Superior (CAPES)
, Cl ´ nica Silveira, and Fundac¸a~o de Amparo a‘ Pesquisa do Estado de Sa~o Paulo
(FAPESP)
Declaration of interest: Not reported.
Trial registration: Not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Computer generated randomisation list.”
Allocation concealment (selection bias) Low risk No relevant statement in published study,
but the authors stated that closed envelopes
were opened only after eligibility criteria
were confirmed (unpublished data)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Medication was administered in an un-
masked fashion.”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No masking, and participants followed up
only by the clinician responsible for the trial
Incomplete outcome data (attrition bias)
All outcomes
High risk 10% lost to follow-up by 14 months.
Slightly higher losses in treatment group (6/
61 versus 4/63), possibly reflecting a need
to keep attending in the hope of eventu-
ally being given antibiotics. No prespeci-
fied duration of trial, as lesion recurrence
was the criterion for ceasing follow-up
Selective reporting (reporting bias) Low risk Recurrence was primary outcome and end-
point for follow-up
BCVA: best corrected visual acuity
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abreu 1988 Prospective randomised double-masked study of clindamycin versus spiramycin in people with ocular toxo-
plasmosis (total studied = 24). Abstract only
Chodos 1961 Compares participants with acute, active posterior retinochoroidal lesions who were given corticosteroids (n
= 45) with a control group given no corticosteroids (n = 22). All participants were treated with spiramycin.
Participants do not appear to have been randomised
Colin 1989 Participants with toxoplasma retinochoroiditis were randomised to oral pyrimethamine and sulfadiazine (n =
15) versus subconjunctival clindamycin (n = 14)
Crespo 1993 Not a randomised controlled trial. Participants with ocular toxoplasmosis were divided into 2 groups and
treated with pyrimethamine and sulfadiazine (n = 36) or clindamycin and sulfadiazine (n = 34)
Jeddi 1997 Participants with unilateral toxoplasma retinochoroiditis were randomised to clindamycin administered sub-
conjunctivally (n = 26) or to oral malocid-sulfadiazine (n = 17)
Rothova 1993b Not a randomised controlled trial. The study compares cohorts of participants with posterior pole lesions
treated according to the antibiotic regimens used in six centres (n = 108). A total of 41 participants in all 6
centres had peripheral lesions and received no treatment
Theodossiadis 1989 Unclear whether participants were randomised. Participants treated with a variety of medications, including
pyrimethamine, sulfadiazine, clindamycin, and cortisone (n = 15) were compared with those given laser
treatment (n = 18)
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D A T A A N D A N A L Y S E S
Comparison 1. Antibiotic versus placebo or no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean change in BCVA at 12
months
1 93 Mean Difference (IV, Fixed, 95% CI) -1.0 [-7.93, 5.93]
2 Recurrence of lesions 3 227 Risk Ratio (M-H, Fixed, 95% CI) 0.26 [0.11, 0.63]
2.1 Recurrent lesions in
participants with acute
retinochoroiditis
2 113 Risk Ratio (M-H, Fixed, 95% CI) 0.20 [0.04, 1.14]
2.2 Recurrent lesions in
participants with chronic
recurrent retinochoroiditis
1 114 Risk Ratio (M-H, Fixed, 95% CI) 0.29 [0.10, 0.81]
3 Improvement in intraocular
inflammation
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4 Adverse events 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Analysis 1.1. Comparison 1 Antibiotic versus placebo or no treatment, Outcome 1 Mean change in BCVA
at 12 months.
Review: Antibiotics versus no treatment for toxoplasma retinochoroiditis
Comparison: 1 Antibiotic versus placebo or no treatment
Outcome: 1 Mean change in BCVA at 12 months
Study or subgroup Antibiotics Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD)[letters] N Mean(SD)[letters] IV,Fixed,95% CI IV,Fixed,95% CI
Felix 2014 (1) 46 21 (18) 47 22 (16) 100.0 % -1.00 [ -7.93, 5.93 ]
Total (95% CI) 46 47 100.0 % -1.00 [ -7.93, 5.93 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours placebo Favours antibiotics
(1) Change in BCVA between baseline and 12 months
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Analysis 1.2. Comparison 1 Antibiotic versus placebo or no treatment, Outcome 2 Recurrence of lesions.
Review: Antibiotics versus no treatment for toxoplasma retinochoroiditis
Comparison: 1 Antibiotic versus placebo or no treatment
Outcome: 2 Recurrence of lesions
Study or subgroup Antibiotics Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Recurrent lesions in participants with acute retinochoroiditis
Acers 1964 1/10 1/10 4.6 % 1.00 [ 0.07, 13.87 ]
Felix 2014 0/46 6/47 29.4 % 0.08 [ 0.00, 1.36 ]
Subtotal (95% CI) 56 57 33.9 % 0.20 [ 0.04, 1.14 ]
Total events: 1 (Antibiotics), 7 (Placebo)
Heterogeneity: Chi2 = 1.84, df = 1 (P = 0.17); I2 =46%
Test for overall effect: Z = 1.81 (P = 0.070)
2 Recurrent lesions in participants with chronic recurrent retinochoroiditis
Silveira 2002 4/55 15/59 66.1 % 0.29 [ 0.10, 0.81 ]
Subtotal (95% CI) 55 59 66.1 % 0.29 [ 0.10, 0.81 ]
Total events: 4 (Antibiotics), 15 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.36 (P = 0.018)
Total (95% CI) 111 116 100.0 % 0.26 [ 0.11, 0.63 ]
Total events: 5 (Antibiotics), 22 (Placebo)
Heterogeneity: Chi2 = 1.73, df = 2 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 2.98 (P = 0.0028)
Test for subgroup differences: Chi2 = 0.11, df = 1 (P = 0.74), I2 =0.0%
0.01 0.1 1 10 100
Favours antibiotics Favours no treatment
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Analysis 1.3. Comparison 1 Antibiotic versus placebo or no treatment, Outcome 3 Improvement in
intraocular inflammation.
Review: Antibiotics versus no treatment for toxoplasma retinochoroiditis
Comparison: 1 Antibiotic versus placebo or no treatment
Outcome: 3 Improvement in intraocular inflammation
Study or subgroup Antibiotics No treatment Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Perkins 1956 15/17 6/12 1.76 [ 0.98, 3.19 ]
0.1 0.2 0.5 1 2 5 10
Favours no treatment Favours antibiotics
Analysis 1.4. Comparison 1 Antibiotic versus placebo or no treatment, Outcome 4 Adverse events.
Review: Antibiotics versus no treatment for toxoplasma retinochoroiditis
Comparison: 1 Antibiotic versus placebo or no treatment
Outcome: 4 Adverse events
Study or subgroup Antibiotics Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Acers 1964 3/10 1/10 3.00 [ 0.37, 24.17 ]
0.01 0.1 1 10 100
Favours antibiotics Favours placebo
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 toxoplasm* and (uveitis or ocular or gondii or gondi or infection or congenital or retinitis or retinochoroiditis or retino-choroiditis)
#2 retinochoroiditis or choroidoretinitis or choroiditis or T gondi or T gondii or Retino-choroiditis or Chorioretinal toxoplasmosis or
Neuroretinitis or Chorioretinitis or pars-planitis or scleritis or papillitis or uveitis
#3 MeSH descriptor Toxoplasmosis, Ocular
#4 MeSH descriptor Toxoplasmosis, Congenital
#5 MeSH descriptor Uveitis
#6 (#1 OR #2 OR #3 OR #4 OR #5)
#7 clindamycin or pyrimethamine or sulphadiazine or sulphadoxine or tetracycline or septrin or azithromycin or atovaquone or fluoro-
cortolone or hydroxynaphthoquinone or lincomycin or trisulfapyrimidine or dapsone-pyrimethamine or trimethoprim-sulfamethox-
azole or daraprim or trimetrexate or piritrexim or leucovorin or co-trimoxazole or malocid-sulfadiazine or malocid-sulphadiazine or
sulfadiazine or sulfadoxine or trisulphapyrimidine or trimethoprim-sulphamethoxazole or Sulfisoxazole or Sulphisoxazole or ciproflo-
xacin or spiramycin or lincosaminide or roxithromycin or doxycycline or ribabutin or rovamycin or miocamycin or dirithromycin or
erythromycin or erythromycin or macrolides or piritrexin or sulfonamides or sulphonamides or sulfamerazine or sulphamerazine or
cotrimoxazole or minocycline or clarithromycin or nifurtimox-pyrimethamine or aerosolized pentamidine or fansidar or clindamycin
hydrochloride or cleocin
#8 MeSH descriptor Clindamycin
#9 MeSH descriptor Pyrimethamine
#10 MeSH descriptor Tetracycline
#11 MeSH descriptor Trimethoprim-Sulfamethoxazole Combination
#12 MeSH descriptor Lincomycin
#13 MeSH descriptor Dapsone
#14 MeSH descriptor Sulfadiazine
#15 MeSH descriptor Trimetrexate
#16 MeSH descriptor Leucovorin
#17 MeSH descriptor Sulfadoxine
#18 MeSH descriptor Sulfisoxazole
#19 MeSH descriptor Ciprofloxacin
#20 MeSH descriptor Spiramycin
#21 MeSH descriptor Doxycycline
#22 MeSH descriptor Miocamycin
#23 MeSH descriptor Erythromycin
#24 MeSH descriptor Macrolides
#25 MeSH descriptor Sulfonamides
#26 MeSH descriptor Sulfamerazine
#27 MeSH descriptor Minocycline
#28 MeSH descriptor Nifurtimox
#29 MeSH descriptor Methotrexate
#30 (#7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR
#22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29)
#31 (#6 AND #30)
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Appendix 2. MEDLINE search strategy
1 randomized controlled trial.pt.
2 (randomized or randomised).ab,ti.
3 placebo.ab,ti.
4 dt.fs.
5 randomly.ab,ti.
6 trial.ab,ti.
7 groups.ab,ti.
8 or/1-7
9 exp animals/
10 exp humans/
11 9 not (9 and 10)
12 8 not 11
13 ((uveitis or ocular or gondii or gondi or infection or congenital or retinitis or retinochoroiditis or retino-choroiditis) adj4 toxo-
plasm$).tw.
14 (retinochoroiditis or choroidoretinitis or choroiditis or T gondi or T gondii or Retino-choroiditis or Chorioretinal toxoplasmosis
or Neuroretinitis or Chorioretinitis or pars-planitis or scleritis or papillitis or uveitis).tw.
15 exp Toxoplasmosis, Ocular/
16 exp Toxoplasmosis, Congenital/
17 exp uveitis/
18 or/13-17
19 (clindamycin or pyrimethamine or sulphadiazine or sulphadoxine or tetracycline or septrin or azithromycin or atovaquone or fluo-
rocortolone or hydroxynaphthoquinone or lincomycin or trisulfapyrimidine or dapsone-pyrimethamine or trimethoprim-sulfamethox-
azole or daraprim or trimetrexate or piritrexim or leucovorin or co-trimoxazole or malocid-sulfadiazine or malocid-sulphadiazine or
sulfadiazine or sulfadoxine or trisulphapyrimidine or trimethoprim-sulphamethoxazole or Sulfisoxazole or Sulphisoxazole or ciproflo-
xacin or spiramycin or lincosaminide or roxithromycin or doxycycline or ribabutin or rovamycin or miocamycin or dirithromycin or
erythromycin or erythromycin or macrolides or piritrexin or sulfonamides or sulphonamides or sulfamerazine or sulphamerazine or
cotrimoxazole or minocycline or clarithromycin or nifurtimox-pyrimethamine or aerosolized pentamidine or fansidar or clindamycin
hydrochloride or cleocin).tw.
20 exp Clindamycin/
21 exp Pyrimethamine/
22 exp Tetracycline/
23 exp Trimethoprim-Sulfamethoxazole-Combination/
24 exp Lincomycin/
25 exp Dapsone/
26 exp Sulfadiazine/
27 exp Trimetrexate/
28 exp Leucovorin/
29 exp Sulfadoxine/
30 exp Sulfisoxazole/
31 exp Ciprofloxacin/
32 exp Spiramycin/
33 exp Doxycycline/
34 exp Miocamycin/
35 exp Erythromycin/
36 exp Macrolides/
37 exp Sulfonamides/
38 exp Sulfamerazine/
39 exp Minocycline/
40 exp Nifurtimox/
41 exp Methotrexate/
42 or/19-41
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43 18 and 41
44 12 and 43
The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville (Glanville 2006).
Appendix 3. EMBASE search strategy
1 exp randomized controlled trial/
2 exp randomization/
3 exp double blind procedure/
4 exp single blind procedure/
5 random$.tw.
6 or/1-5
7 (animal or animal experiment).sh.
8 human.sh.
9 7 and 8
10 7 not 9
11 6 not 10
12 exp clinical trial/
13 (clin$ adj3 trial$).tw.
14 ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
15 exp placebo/
16 placebo$.tw.
17 random$.tw.
18 exp experimental design/
19 exp crossover procedure/
20 exp control group/
21 exp latin square design/
22 or/12-21
23 22 not 10
24 23 not 11
25 exp comparative study/
26 exp evaluation/
27 exp prospective study/
28 (control$ or prospectiv$ or volunteer$).tw.
29 or/25-28
30 29 not 10
31 30 not (11 or 23)
32 11 or 24 or 31
33 ((uveitis or ocular or gondii or gondi or infection or congenital or retinitis or retinochoroiditis or retino-choroiditis) adj4 toxo-
plasm$).tw.
34 (retinochoroiditis or choroidoretinitis or choroiditis or T gondi or T gondii or Retino-choroiditis or Chorioretinal toxoplasmosis
or Neuroretinitis or Chorioretinitis or pars-planitis or scleritis or papillitis or uveitis).tw.
35 exp Toxoplasmosis/
36 exp Congenital Toxoplasmosis/
37 exp uveitis/
38 or/33-37
39 (clindamycin or pyrimethamine or sulphadiazine or sulphadoxine or tetracycline or septrin or azithromycin or atovaquone or fluo-
rocortolone or hydroxynaphthoquinone or lincomycin or trisulfapyrimidine or dapsone-pyrimethamine or trimethoprim-sulfamethox-
azole or daraprim or trimetrexate or piritrexim or leucovorin or co-trimoxazole or malocid-sulfadiazine or malocid-sulphadiazine or
sulfadiazine or sulfadoxine or trisulphapyrimidine or trimethoprim-sulphamethoxazole or Sulfisoxazole or Sulphisoxazole or ciproflo-
xacin or spiramycin or lincosaminide or roxithromycin or doxycycline or ribabutin or rovamycin or miocamycin or dirithromycin or
erythromycin or erythromycin or macrolides or piritrexin or sulfonamides or sulphonamides or sulfamerazine or sulphamerazine or
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cotrimoxazole or minocycline or clarithromycin or nifurtimox-pyrimethamine or aerosolized pentamidine or fansidar or clindamycin
hydrochloride or cleocin).tw.
40 exp Clindamycin/
41 exp Pyrimethamine/
42 exp Tetracycline/
43 exp Sulfadoxine Trimethoprim/
44 exp Lincomycin/
45 exp Dapsone/
46 exp Sulfadiazine/
47 exp Trimetrexate/
48 exp folinic acid/
49 exp Sulfadoxine/
50 exp Sulfisoxazole/
51 exp Ciprofloxacin/
52 exp Spiramycin/
53 exp Doxycycline/
54 exp Miokamycin/
55 exp Erythromycin/
56 exp Macrolide/
57 exp Sulfonamide/
58 exp Sulfamerazine/
59 exp Minocycline/
60 exp Nifurtimox/
61 exp Methotrexate/
62 or/39-61
63 38 and 61
64 32 and 63
Appendix 4. LILACS search strategy
Toxoplasm$ or Coroidoretinit$ or Coroidit$ or Choroiditis or Retinitis or Retinite or Retinites or T-gondi or T-gondii or Gondi or
gondii or Neuroretinit$ or Neuro or retinit$ or Pars-planitis or Parsplanitis or Planitis or Scleritis or Esclerit$ or Papillitis or Papilit$ or
Uveitis orUveit$ and antibiotic$ or clindamycin or pyrimethamine or sulphadiazine or sulphadoxine or tetracycline or septrin or azithro-
mycin or atovaquone or fluorocortolone or hydroxynaphthoquinone or lincomycin or trisulfapyrimidine or dapsone-pyrimethamine
or trimethoprim-sulfamethoxazole or daraprim or trimetrexate or piritrexim or leucovorin or co-trimoxazole or malocid-sulfadiazine
or malocid-sulphadiazine or sulfadiazine or sulfadoxine or trisulphapyrimidine or trimethoprim-sulphamethoxazole or Sulfisoxazole
or Sulphisoxazole or ciprofloxacin or spiramycin or lincosaminide or roxithromycin or doxycycline or ribabutin or rovamycin or mio-
camycin or dirithromycin or erythromycin or erythromycin or macrolides or piritrexin or sulfonamides or sulphonamides or sulfamer-
azine or sulphamerazine or cotrimoxazole or minocycline or clarithromycin or nifurtimox-pyrimethamine or aerosolized pentamidine
or fansidar or clindamycin hydrochloride or cleocin
Appendix 5. ISRCTN search strategy
toxoplasmosis or retinochoroiditis
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Appendix 6. ClinicalTrials.gov search strategy
Toxoplasmosis OR retinochoroiditis
Appendix 7. ICTRP search strategy
toxoplasmosis or retinochoroiditis
WH A T ’ S N E W
Last assessed as up-to-date: 22 February 2016.
Date Event Description
22 February 2016 New search has been performed Electronic searches were updated
22 February 2016 New citation required but conclusions have not
changed
One new trial met the inclusion criteria (Felix 2014)
H I S T O R Y
Protocol first published: Issue 3, 2000
Review first published: Issue 1, 2002
Date Event Description
27 June 2011 New search has been performed Issue 8, 2011: Updated searches yielded no new trials.
’Risk of bias’ tables completed for included studies and
new subheadings activated
16 October 2008 Amended Converted to new review format
23 January 2008 New search has been performed Updated search in January 2008 found no new trials
14 November 2001 New citation required and conclusions have changed Substantive amendment
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C O N T R I B U T I O N S O F A U T H O R S
2016 update
EP: evaluated studies for inclusion and commented on drafts of the report
SB: assisted in collating the search results, evaluated studies for inclusion, worked on the ’Summary of findings’ table, wrote the Plain
language summary and draft of the update report
RG: reviewed the edited draft and is the guarantor for the review
MS: commented on the update draft of the report
D E C L A R A T I O N S O F I N T E R E S T
EP: None known.
SB: None known.
RG: None known.
MS: None known.
S O U R C E S O F S U P P O R T
Internal sources
• Centre for Paediatric Epidemiology and Biostatistics, Institute of Child Health, UK.
External sources
• National Institute for Health Research (NIHR), UK.
• Richard Wormald, Co-ordinating Editor for the Cochrane Eyes and Vision (CEV) acknowledges financial support for his CEV
research sessions from the Department of Health through the award made by the National Institute for Health Research to
Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology for a Specialist Biomedical Research Centre
for Ophthalmology.
• The NIHR also funds the CEV Editorial Base in London.
The views expressed in this publication are those of the authors and not necessarily those of the NIHR, NHS, or the Department of
Health.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We have included a ’Summary of findings’ table in the current (2016) update of this review.
We included ’intravitreal’ in the routes of administration of the antibiotic, but did not identify any trials versus placebo or no treatment
for this route of administration.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Administration, Oral; Anti-Bacterial Agents [administration & dosage; ∗therapeutic use]; Chorioretinitis [∗drug therapy; parasitology];
Drug Combinations; Pyrimethamine [therapeutic use]; Randomized Controlled Trials as Topic; Recurrence; Secondary Prevention;
Sulfadiazine [therapeutic use]; Sulfamerazine [therapeutic use]; Sulfamethazine [therapeutic use]; Toxoplasmosis,Ocular [complications;
∗drug therapy]; Trimethoprim, Sulfamethoxazole Drug Combination [administration & dosage; therapeutic use]; Visual Acuity;
Watchful Waiting
MeSH check words
Adult; Child; Humans
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